Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

Blakeruss1 Jul. 15 at 3:14 AM

$CRDF confirmed deal!

0 · Reply

freefall63108 Jul. 15 at 2:16 AM

$CRDF "Lad" on Ymb reporting Pfizer licensing deal...

2 · Reply

rag2riches Jul. 14 at 10:08 PM

$CRDF nms lawyers going to reach for every trick in the book in order to try to extend this process. If their case was rock solid they wouldnt be reaching for draws. Their offensive approach has now pivoted to defense to run the clock (run out of money) for CRDF.

1 · Reply

Blakeruss1 Jul. 14 at 9:58 PM

$CRDF big news on horizon

1 · Reply

Blakeruss1 Jul. 14 at 9:58 PM

$CRDF all we be known tmrw

0 · Reply

JN75 Jul. 14 at 9:19 PM

$CRDF

0 · Reply

PSDL75 Jul. 14 at 8:55 PM

$CRDF I guess whoever is killing this every day wanted to kill it again today.

0 · Reply

Blakeruss1 Jul. 14 at 8:16 PM

$CRDF up huge after hours. News must be out

1 · Reply

Cutlass Jul. 14 at 8:08 PM

$CRDF

0 · Reply

Blakeruss1 Jul. 14 at 8:04 PM

$CRDF beautiful day !!! Tmrw we fly!!!

0 · Reply

Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital

Jun 4, 2026, 10:30 AM EDT - 5 weeks ago

Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T16:55:09.000Z - 5 weeks ago

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

2026-06-03T16:07:35.000Z - 5 weeks ago

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

Jun 3, 2026, 8:30 AM EDT - 5 weeks ago

Cardiff Oncology Transcript: Status update

Jun 3, 2026, 8:30 AM EDT - 5 weeks ago

Cardiff Oncology Press release: Status update

Jun 3, 2026, 8:30 AM EDT - 5 weeks ago

Cardiff Oncology Slides: Status update

2026-06-02T14:11:15.000Z - 6 weeks ago

Cardiff Oncology announces results from CRDF-004 trial

Jun 2, 2026, 9:06 AM EDT - 6 weeks ago

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Jun 1, 2026, 4:01 PM EDT - 6 weeks ago

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

2026-06-01T10:28:20.000Z - 6 weeks ago

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

2026-06-01T10:26:56.000Z - 6 weeks ago

Cardiff Oncology says NMS terminating license agreement

2026-06-01T10:26:21.000Z - 6 weeks ago

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

May 21, 2026, 5:00 PM EDT - 7 weeks ago

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

2026-05-14T21:00:37.000Z - 2 months ago

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

2026-05-14T20:59:48.000Z - 2 months ago

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

May 14, 2026, 4:10 PM EDT - 2 months ago

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 2 months ago

Cardiff Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Cardiff Oncology Earnings release: Q1 2026

Apr 28, 2026, 4:01 PM EDT - 2 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Cardiff Oncology Proxy statement: Proxy filing

Apr 21, 2026, 10:00 AM EDT - 3 months ago

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

2026-04-17T20:14:54.000Z - 3 months ago

Cardiff Oncology to present preclinical data on onvansertib

Apr 17, 2026, 4:01 PM EDT - 3 months ago

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

2026-04-09T20:11:39.000Z - 3 months ago

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

ACRS

Apr 9, 2026, 4:01 PM EDT - 3 months ago

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Cardiff Oncology Transcript: KOL event

Mar 20, 2026, 7:00 AM EDT - 4 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Feb 26, 2026, 4:01 PM EST - 4 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Feb 25, 2026, 1:20 PM EST - 4 months ago

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-25T12:21:13.000Z - 4 months ago

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

Feb 24, 2026, 4:30 PM EST - 5 months ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Feb 24, 2026, 7:00 AM EST - 5 months ago

Cardiff Oncology Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 5 months ago

Cardiff Oncology Annual report: Q4 2025

Feb 19, 2026, 7:00 AM EST - 5 months ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-28T11:15:48.000Z - 5 months ago

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

Jan 27, 2026, 8:30 AM EST - 6 months ago

Cardiff Oncology Transcript: Study result

Jan 27, 2026, 8:30 AM EST - 6 months ago

Cardiff Oncology Press release: Study result

2026-01-27T12:16:42.000Z - 6 months ago

Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down

2026-01-27T12:10:44.000Z - 6 months ago

Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib

Jan 27, 2026, 7:05 AM EST - 6 months ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Jan 7, 2026, 7:00 AM EST - 6 months ago

Cardiff Oncology Slides: Company presentation

2026-01-05T14:01:22.000Z - 6 months ago

Cardiff Oncology initiated with an Outperform at Noble Capital

Dec 11, 2025, 4:00 PM EST - 7 months ago

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Dec 8, 2025, 4:05 PM EST - 7 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 7:00 AM EST - 7 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 2, 2025, 9:30 AM EST - 8 months ago

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 8 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 8 months ago

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:30 AM EST - 8 months ago

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-06T23:05:40.000Z - 8 months ago

Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M

Nov 6, 2025, 4:05 PM EST - 8 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:00 PM EST - 8 months ago

Cardiff Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Cardiff Oncology Quarterly report: Q3 2025

Nov 4, 2025, 4:01 PM EST - 9 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 9, 2025, 2:00 PM EDT - 9 months ago

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Sep 9, 2025, 10:30 AM EDT - 11 months ago

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 11 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Transcript: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Press release: Study Update

Jul 29, 2025, 4:30 PM EDT - 1 year ago

Cardiff Oncology Slides: Study Update

Jul 29, 2025, 4:07 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Earnings release: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q2 2025

Jun 17, 2025, 4:39 PM EDT - 1 year ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Mar 5, 2025, 11:50 AM EST - 1 year ago

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Annual report: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Transcript: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Press release: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Slides: Study Result

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q2 2024

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

May 29, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 1:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 20, 2024, 2:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q1 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 4, 2024, 1:30 PM EST - 2 years ago

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Annual report: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Slides: Q4 2023

Feb 29, 2024, 4:07 PM EST - 2 years ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 2 years ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 2 years ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 29, 2023, 10:00 AM EST - 2 years ago

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Slides: Q3 2023

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Cardiff Oncology Slides: Investor Presentation

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Blakeruss1 Jul. 15 at 3:14 AM

$CRDF confirmed deal!

0 · Reply

freefall63108 Jul. 15 at 2:16 AM

$CRDF "Lad" on Ymb reporting Pfizer licensing deal...

2 · Reply

rag2riches Jul. 14 at 10:08 PM

1 · Reply

Blakeruss1 Jul. 14 at 9:58 PM

$CRDF big news on horizon

1 · Reply

Blakeruss1 Jul. 14 at 9:58 PM

$CRDF all we be known tmrw

0 · Reply

JN75 Jul. 14 at 9:19 PM

$CRDF

0 · Reply

PSDL75 Jul. 14 at 8:55 PM

$CRDF I guess whoever is killing this every day wanted to kill it again today.

0 · Reply

Blakeruss1 Jul. 14 at 8:16 PM

$CRDF up huge after hours. News must be out

1 · Reply

Cutlass Jul. 14 at 8:08 PM

$CRDF

0 · Reply

Blakeruss1 Jul. 14 at 8:04 PM

$CRDF beautiful day !!! Tmrw we fly!!!

0 · Reply

Blakeruss1 Jul. 14 at 6:05 PM

$CRDF building massive and fortified base at 1.35!!!!

1 · Reply

Blakeruss1 Jul. 14 at 5:54 PM

$CRDF wohoo!! Consolidation and stability.

0 · Reply

mgmuc Jul. 14 at 4:58 PM

$CRDF MOTION for Leave to File Excess Pages Unopposed Motion for Leave to Exceed Page Limit by Nerviano Medical Sciences S.r.l..(Fishman, Deborah)

3 · Reply

Huber65 Jul. 14 at 4:57 PM

$CRDF doesn’t look like much . Motion for leave to file excess pages

0 · Reply

jakeguess Jul. 14 at 4:19 PM

$CRDF new court filing

1 · Reply

jrh34 Jul. 14 at 3:58 PM

$CRDF wild west about to come to town

0 · Reply

Blakeruss1 Jul. 14 at 3:15 PM

$CRDF if close 1.36 or above I think we go parabolic tmrw. Close week above 10 easy

0 · Reply

BioGypsy Jul. 14 at 3:01 PM

$CRDF less than 60k shares traded. Sleeping giant…..

0 · Reply

Blakeruss1 Jul. 14 at 2:46 PM

$CRDF strong. Stable. Invincible

0 · Reply

Blakeruss1 Jul. 14 at 1:37 PM

$CRDF will all be known end of day

0 · Reply

PMD777 Jul. 14 at 11:37 AM

$CRDF so are we going to see step 1 Aug 7th? "For investors, I would think of this as a binary legal overhang rather than a situation where the outcome can be estimated with high confidence. The clinical data for onvansertib may support the company's value, but if Cardiff were ultimately to lose its rights to the drug, it would be a severe setback. Conversely, if the dispute is resolved in Cardiff's favor, a major uncertainty would be removed."

3 · Reply

BioGypsy Jul. 14 at 8:51 AM

$CRDF https://www.nature.com/articles/s41375-026-03055-5

1 · Reply

Market Cap	92.30M
Revenue (ttm)	590,000.00
Net Income (ttm)	-45.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,771.19%
Debt to Equity Ratio	0.00

Volume	664,500
Avg Vol	1,353,450
Day's Range	N/A - N/A
Shares Out	68.37M
Stochastic %K	48%
Beta	1.44
Analysts	Sell
Price Target	$5.58